Repligen (NASDAQ:RGEN) Updates FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.50-1.58 for the period, compared to the consensus earnings per share estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million. Repligen also updated its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Trading Down 1.7 %

NASDAQ:RGEN traded down $2.56 during trading hours on Thursday, hitting $147.91. The company had a trading volume of 49,603 shares, compared to its average volume of 657,073. The company has a market capitalization of $8.28 billion, a PE ratio of -406.66, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. The stock has a 50-day moving average price of $141.59 and a 200 day moving average price of $144.78. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the firm earned $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. On average, equities research analysts predict that Repligen will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RGEN shares. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Wolfe Research assumed coverage on Repligen in a research note on Thursday. They set a “peer perform” rating for the company. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.